Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

DICE Therapeutics, Inc. (DICE)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
29.08-2.79 (-8.75%)
At close: 04:00PM EST
29.08 0.00 (0.00%)
After hours: 04:20PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close31.87
Open31.15
Bid21.00 x 1000
Ask40.00 x 1300
Day's Range28.76 - 31.80
52 Week Range23.16 - 40.50
Volume246,987
Avg. Volume201,785
Market Cap1.112B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est49.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for DICE

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • DICE Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 12/01/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • GlobeNewswire

    DICE Therapeutics to Present at November Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Nov. 16, 2021 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced that management will participate in the following investor conferences in November: 33rd Annual Piper Sandler Virtual Healthcare Conference. A pre-recorded fireside chat with DICE

  • GlobeNewswire

    DICE Therapeutics Reports Third Quarter 2021 Financial Results and Recent Highlights

    Dosed first healthy volunteers in Phase 1 clinical trial of oral IL-17 antagonist S011806Successfully completed $234.6 million upsized initial public offering SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today reported financial results and

  • GlobeNewswire

    DICE Therapeutics Initiates Phase 1 Clinical Trial of S011806 for the Treatment of Psoriasis

    SOUTH SAN FRANCISCO, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced that the first healthy volunteer has been dosed in the Company’s Phase 1 clinical trial of S011806. S011806 is an orally-available, small molecule antagonist of the pro-inflammator

Advertisement
Advertisement